Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
PaperCitations, authors & open-access status
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 545 citations, 2009 year and closed oa status.
545
Citations
2009
Year
closed
OA Status